- Home
- FAX vs PSNL Comparison
FAX vs PSNL Comparison
Compare FAX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | PSNL |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 650.6M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FAX | PSNL |
|---|---|---|
| Price | $15.30 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 184.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.99 | $2.83 |
| 52 Week High | $16.95 | $11.50 |
Technical Indicators
Market Signals| Indicator | FAX | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 34.61 |
| Support Level | $15.02 | $4.31 |
| Resistance Level | $15.48 | $6.94 |
| Average True Range (ATR) | 0.20 | 0.71 |
| MACD | -0.08 | -0.19 |
| Stochastic Oscillator | 37.35 | 5.95 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.